Related Experiment Video
Updated: Apr 15, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
18.6K
LCZ696: the next step in improving RAS inhibition?
1Temple University School of Medicine (Clinical Campus), 1239 Shady Avenue, Pittsburgh, PA, 15232, USA, gradmanmd@aol.com.
Current Hypertension Reports
|April 3, 2015
Summary
LCZ696, a combination of valsartan and sacubitril, shows superiority over enalapril in heart failure patients. Further studies are needed to confirm its role in hypertension management and vascular protection.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- LCZ696 is a novel drug combining valsartan (angiotensin receptor blocker) and sacubitril (neprilysin inhibitor).
- The PARADIGM-HF trial demonstrated LCZ696's efficacy in heart failure with reduced ejection fraction.
Purpose of the Study:
- To evaluate the efficacy and tolerability of LCZ696 in hypertension.
- To assess the potential of LCZ696 to displace existing renin-angiotensin system (RAS) blockers.
Main Methods:
- Two large hypertension studies were conducted to assess LCZ696's antihypertensive effects.
- Tolerability was compared to valsartan and placebo; potency was compared to amlodipine.
Main Results:
- LCZ696 demonstrated potent and effective antihypertensive action.
- Tolerability was similar to valsartan and placebo, with potency comparable to amlodipine.
- No angioedema cases were reported in hypertension trials, though few Black patients were studied.
Conclusions:
- LCZ696 shows promise as an antihypertensive agent.
- Long-term outcome data and demonstration of renal and vascular protection are crucial for its adoption over current RAS blockers in hypertension.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:33Hormonal Regulation
37.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
37.4K
01:29Hypertension II: Pathophysiology
1.6K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K